Company / SG&A Expense
Edwards Lifesciences SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$2.1B
FY2025
5-year range
$1.4B / $2.1B
FY2021-FY2025
Trend
+16.5%
vs FY2024
Sector context
#26 of 158
Health Care
What the data says
Edwards Lifesciences's sg&a expense of $2.1B is higher than 84% of companies in the Health Care sector (FY2025). SG&A Expense has increased for 3 consecutive years, from $1.4B in FY2022 to $2.1B in FY2025.
Based on SEC 10-K filings.
$2.1B in FY2025 with a 5-year CAGR of +11.2%. Top quartile in the Health Care sector.
Increased from $1.5B to $2.1B over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +15.4%
- 5-Year CAGR
- +11.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 16% in Health CareTop 84% of 158This company $2.1B Sector average $175.9B
▼
-98.8% below sector average
Key checks
Key Insights
- Edwards Lifesciences's sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +11.2%, indicating consistent growth.
- In FY2025, sg&a expense increased 16.5% year-over-year.
- Ranks #26 out of 158 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.1B | +16.5% |
| FY2024 | $1.8B | +19.8% |
| FY2023 | $1.5B | +10.0% |
| FY2022 | $1.4B | -9.1% |
| FY2021 | $1.5B | +21.6% |
| FY2020 | $1.2B | -1.1% |
| FY2019 | $1.2B | +14.1% |
| FY2018 | $1.1B | +9.9% |
| FY2017 | $990.8M | +9.5% |
| FY2016 | $904.7M | +6.3% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026